The ocular manifestations of inflammatory bowel disease

Current Opinion in Ophthalmology

Volumn 17, Issue 6, 2006, Pages 538-544

  Taylor, Simon R J ^a   McCluskey, Peter ^b   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Corticosteroids; Episcleritis; Inflammatory bowel disease; Scleritis; Uveitis

Indexed keywords

ADALIMUMAB; ANTIMETABOLITE; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW DEPRESSION; CHRONIC HEPATITIS; CLINICAL FEATURE; CROHN DISEASE; ENTERITIS; EPISCLERITIS; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; OPTIC NEURITIS; ORBIT DISEASE; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SCLERITIS; UVEITIS;

ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES; DIAGNOSIS, DIFFERENTIAL; EYE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

EID: 33750432864     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3280109461     Document Type: Review

References (56)

1. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39:690-697.
2. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29-34.
3. Schorr-Lesnick B, Brandt LJ. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83:216-223.
4. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92:5S-11S.
5. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99:2393-2404.
6. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118:274-278.
7. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004; 3:394-400.
8. Grant IR. Zoonotic potential of Mycobacterium avium ssp paratuberculosis: the current position. J Appl Microbiol 2005; 98:1282-1293. This is a useful review of the current state of knowledge regarding the involvement of Map in the pathogenesis of IBD.
9. Shafran I, Kugler L, El-Zaatari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34:22-28.
10. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44:1-13.
11. Duker JS, Brown GC, Brooks L. Retinal vasculitis in Crohn's disease. Am J Ophthalmol 1987; 103:664-668.
12. Hudson M, Chitolie A, Hutton RA, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38:733-737.
13. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55:401-412.
14. Billson FH, Reich J, Hopkins IJ. Visual failure in a patient with ulcerative colitis treated by clioquinol. Lancet 1972; 1:1015-1016.
15. Hopkins DJ, Horan E, Burton IL, et al. Ocular disorders in a series of 332 patients with Crohn's disease. Br J Ophthalmol 1974; 58:732-737.
16. Knox DL, Schachat AP, Mustonen E. Primary, secondary and coincidental ocular complications of Crohn's disease. Ophthalmology 1984; 91:163-173.
17. Rankin GB, Watts HD, Melnyk CS, et al. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77:914-920.
18. Wright R, Lumsden K, Luntz MH, et al. Abnormalities of the sacro-iliac joints and uveitis in ulcerative colitis. Q J Med 1965; 34:229-236.
19. Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 1994; 118:601-611.
20. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997; 115:61-64.
21. Salmon JF, Wright JP, Murray AD. Ocular inflammation in Crohn's disease. Ophthalmology 1991; 98:480-484.
22. Evans PJ, Eustace P. Scleromalacia perforans associated with Crohn's disease treated with sodium versenate (EDTA). Br J Ophthalmol 1973; 57:330-335.
23. Sedwick LA, Klingele TG, Burde RM, et al. Optic neuritis in inflammatory bowel disease. J Clin Neuroophthalmol 1984; 4:3-6.
24. Knox DL, Snip RC, Stark WJ. The keratopathy of Crohn's disease. Am J Ophthalmol 1980; 90:862-865.
25. Geerards AJ, Beekhuis WH, Remeyer L, et al. Crohn's colitis and the cornea. Cornea 1997; 16:227-231.
26. McCannel CA, Holland GN, Helm CJ, et al. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996; 121:35-46.
27. Turkcapar N, Toruner M, Soykan I, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006; 26:663-668. This interesting article examines the prevalence of spondyloarthropathy in patients with IBD and evaluates HLA association of extra-intestinal disease manifestations.
28. Banares A, Jover JA, Fernandez-Gutierrez B, et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis Rheum 1997; 40:358-370.
29. Verbraak FD, Schreinemachers MC, Tiller A, et al. Prevalence of subclinical anterior uveitis in adult patients with inflammatory bowel disease. Br J Ophthalmol 2001; 85:219-221.
30. Ernst BB, Lowder CY, Meisler DM, et al. Posterior segment manifestations of inflammatory bowel disease. Ophthalmology 1991; 98:1272-1280.
31. Benson WE. Posterior scleritis. Surv Ophthalmol 1988; 32:297-316.
32. Gass JDM. Stereoscopic atlas of macular diseases diagnosis and treatment. St. Louis: CV Mosby Co.; 1987.
33. Weinstein JM, Koch K, Lane S. Orbital pseudotumor in Crohn's colitis. Ann Ophthalmol 1984; 16:275-278.
34. Leibovitch I, Galanopoulos A, Selva D. Suppurative granulomatous myositis of an extra-ocular muscle in Crohn's disease. Am J Gastroenterol 2005; 100:2136-2137.
35. Greenfield SM, Teare JP, Whitehead MW, et al. Amaurosis fugax, Crohn's disease and the anticardiolipin antibody. Lupus 1993; 2:271-273.
36. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99:2235-2241.
37. Aichbichler BW, Petritsch W, Reicht GA, et al. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1999; 44:852-856.
38. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000; 11:478-483.
39. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006; 17:163-167. This is a useful summary of corticosteroid-induced ocular hypertension and glaucoma.
40. Esterl RM Jr, Gupta N, Garvin PJ. Permanent blindness after cyclosporine neurotoxicity in a kidney-pancreas transplant recipient. Clin Neuropharmacol 1996; 19:259-266.
41. Nakla ML, Heffler KF. Ophthalmologic effects of bowel disease. Gastroenterol Clin North Am 1998; 27:697-711; vii.
42. Awotesu O, Missotten T, Pitcher MC, et al. Uveitis in a patient receiving rifabutin for Crohn's disease. J R Soc Med 2004; 97:440-441.
43. Heuer DK, Gager WE, Reeser FH. Ischemic optic neuropathy associated with Crohn's disease. J Clin Neuroophthalmol 1982; 2:175-181.
44. Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108:1134-1139.
45. Richter M, Zahn S, Richter H, et al. Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy. J Heart Lung Transplant 2004; 23:1405-1413.
46. Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112:1472-1477. This is a retrospective case series of 84 patients treated with MMF reporting a high level of success as a steroid-sparing agent and a manageable side-effect profile.
47. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term follow-up. J Ocul Pharmacol 1985; 1:369-382.
48. Hakin KN, Ham J, Lightman SL. Use of cyclosporin in the management of steroid dependent nonnecrotising scleritis. Br J Ophthalmol 1991; 75: 340-341.
49. Towler HM, Cliffe AM, Whiting PH, et al. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye 1989; 3 (Pt 3):282-287.
50. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998; 6:101-109.
51. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J Exp Med 2004; 200:277-285.
52. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006; 33:231-237. This is a useful review of the current evidence available regarding the use of anti-TNF therapy in ocular inflammatory disease.
53. Murray PI, Sivaraj RR. Anti-TNF-alpha therapy for uveitis: Behcet and beyond. Eye 2005; 19:831-833.
54. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44:1008-1011.
55. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
56. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342:173-174.